mCRPC in focus
Transcript: CONTACT-02
Dr Neeraj Agarwal, Professor Karim Fizazi, Dr Bárbara Vieira Lima Aguiar Melão, and Professor Axel Merseburger
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Now, before we conclude, Axel, I'd like to have your overview on the CONTACT-02 trial, which was the combination of cabozantinib plus atezolizumab compared to a alternate ARPI and patients with mCRPC with prior progression on ARPI. And let's keep it brief because we don't have the results available, we don't have the combination available in the clinic. And after that, we'll move on to question answer session.
Perfect, Neeraj, and thank you for leadership in the CONTACT-02 trial, which you perfectly and briefly introduced into the clinical trials seen here. And I think it is important because in this situation, as you mentioned, mCRPC men with visceral metastasis, 25% had liver metastasis. They all had an RP before, 20% had docetaxel in mHSPC before, so this is really a very difficult to treat patient population.
So here we have an unmet need, what to do with those patients after we have done a lot with radioligand therapy and so on. So really here we have the situation, what's next? And I think it was a good idea to look at cabo again, which we know from RCC, renal cancer. And now we had some data from the COSMIC trials years ago showing some activity. And now with a combination of cabozantinib and atezolizumab, this was a new idea randomised against the second RP, abiraterone or enzalutamide. 567 patients were randomised one-to-one and it was a positive trial. PFS was longer, 6.3 months compared to 4.3 months.
We can argue and we can discuss if this couple months makes a difference, but we're looking at some subgroups, those very difficult to treat men with liver metastasis, so signal was stronger and I'm looking forward to see the press release in a while on the overall survival benefit, which we can expect and to see the data in one of the upcoming conferences. So in summary, this is the only phase 3 trial, often immune checkpoint inhibitor based regimen that showed the benefit in advanced mCRPC. So congratulation Neeraj on that and I think this may close an unmet need here in the last-line treatment of mCRPC. Happy to hear comments to keep it short, thank you.
Yeah, thank you very much. Let's look forward to the final results, which hopefully we'll see in a meeting in the near future.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.